1 Min Read
April 18 (Reuters) - Xoma Corp
* Xoma presents positive data from PTH1R monoclonal antibody program
* Xoma corp says PTH1R antagonism in vitro by anti-PTH1R MAB translated to potent in vivo activity Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.